KD Pharma acquires phytoextract and CBD manufacturing assets

Published: 12-Apr-2021
Manufacturing Finance

The transaction is aimed to advance KD Pharma’s cannabinoid manufacturing strategy

The KD Pharma Group has acquired the manufacturing assets of a Swiss-based cannabinoid manufacturer. The assets give KD Pharma access to technology for producing APIs based on phytocannabinoids and other plant extracts. The technology further expands KD’s lipid technology portfolio and can be used in combination with its other fractionation and separation technologies.

Oscar Groet, CEO of the KD Pharma Group said: “We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts, and these assets give KD Pharma additional pathways to develop new products for this emerging market.”

The KD Pharma Group has also licensed an extraction method from Herbolea Biotech and expects to have a complete, licensed cGMP manufacturing facility online by the end of the year.

  • Companies:
  • KD Pharma Group
See more

You may also like

Finance

KD Pharma Group completes acquisition of dsm-firmenich's Marine Lipids business

Read more
The transaction positions KD Pharma Group as the largest omega-3 manufacturer in the world

Trending Articles

  1. UNPA honors Shaheen Majeed and late founder Dr. Muhammed Majeed for their contributions Sabinsa receives Lifetime Achievement Award and Excellence in Leadership recognition at SupplySide West
  2. Rousselot's softgel technology, StabiCaps, granted Brazilian patent The gelatin-based capsule technology optimises the release of nutraceuticals from a softgel, allowing functional ingredient manufacturers to produce efficacious and bioavailable dietary supplements
  3. Arla Foods Ingredients one step closer to getting the Volac acquisition go-ahead This follows the UK Competition and Market Authority's approval of Arla's acquisition of Volac's whey nutrition business
  4. Miura Partners becomes the majority shareholder of HealthTech BioActives The nutraceutical specialist will now be able to grow its functional health, taste modulation and animal nutrition divisions
  5. Vitaquest hires David Alcaraz as Senior Vice President, Quality Assurance Alcaraz brings nearly 20 years of experience in quality management to the role

Upcoming event

Fi Europe 2024

19-21 November 2024 | Exhibition | Frankfurt, Germany See all

You may also like

Finance

KD Pharma Group completes acquisition of dsm-firmenich's Marine Lipids business

The transaction positions KD Pharma Group as the largest omega-3 manufacturer in the world
Finance

KD Pharma secures dsm-firmenich's MEG-3 fish oil business in strategic acquisition

KD Pharma will gain all of the MEG-3's assets, including two production facilities and around 200 employees
Finance

KD Pharma acquires Rohner manufacturing assets

The KD Pharma Group has an existing site in the United Kingdom, as well as a contract softgel manufacturing site in the United States
Manufacturing

GEA delivers skid-based evaporation plant to prepare a silver nitrate solution

In May 2020, GEA received a repeat order for an evaporation plant for the treatment of silver nitrate from the production of omega-3 fatty acids from fish oil from KD Pharma Group
Manufacturing

KD Pharma Group acquires UK manufacturing site

Facility will expand KD Pharma’s capacity for manufacturing omega-3-based intermediates used in producing active pharmaceutical ingredients (APIs)
Ingredients

Marine Ingredients announces merger with KD-Pharma

Both parties agreed not to disclose financial details of the transaction, but did announce that all entities on both sides will merge into a single group
Manufacturing

Happy Plant Protein secures €1.8m to develop and license its plant-based protein ingredients

The manufacturing process developed by Happy Plant Protein can reduce plant-based protein production costs by up to 90%, while also creating functional food products with a 70–80% protein content
Subscribe now